Search Results for “cancer” – Page 56 – media

Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 817
- November 16, 2017
cancer larotrectinib Market Views therapy TRK
FDA Approves Genentech’s Alecensa Lung Cancer Treatment

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
- Source: Pharmpro
- 596
- November 9, 2017
ALK FDA New Approvals NSCLC sNDA
Cancer cells destroyed in just 3 days with new technique

Cancer cells are relentless, possessing the vexatious ability to develop resistance to current therapies and making the disease hugely challenging to treat. However, an exciting new study may have identified cancer's weak spot; the discovery has already led to the near-eradication of the disease in cell cultures.
- Source: medicalnewstoday
- 670
- November 8, 2017
cancer cell chromatin Researches
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

The U.S. Food and Drug Administration(FDA) has expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
- Source: Worldpharmanews
- 439
- November 8, 2017
BRAF V600 ECD FDA Zelboraf (vemurafenib)
Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
- Source: Pharmatimes
- 484
- November 7, 2017
avelumab Company Insight mMCC skin cancer
Men with low testosterone less likely to have prostate cancer

New research suggests that men with abnormally low levels of testosterone are less likely to develop prostate cancer in their lifetime. The new study was carried out by scientists at the University of Oxford in the United Kingdom, and the findings were presented at the National Cancer Research Institute (NCRI) Cancer Conference, held in Liverpool, U.K.
- Source: medicalnewstoday
- 568
- November 7, 2017
cancer NCRI prostate Researches testosterone
Cancer-detecting start-up Grail is seeking more funding, mere months after raising $900 million

Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. The company had previously raised $100 million in 2016.
- Source: Cnbc
- 457
- November 2, 2017
cancer detection funding Market Views
Scientists discover 27 genes that could halt cancer

From an analysis of more than 2,000 tumors spanning 12 types of human cancer, scientists have identified 27 new genes that could stop the disease in its tracks.
- Source: medicalnewstoday
- 671
- November 2, 2017
cancer Researches suppressor genes tumor
New Use of A.I. Accurately Detected Cancer 86 Percent of the Time

The quest to better detect cancer has made a potentially huge strides. A study out of Yokohama, Japan, has potentially harnessed artificial intelligence to help detect colorectal cancer even before benign tumors become malignant.
- Source: inverse
- 715
- November 1, 2017
Artificial Intelligence colorectal cancer Market Views
Novartis Slams Down $3.9B for This French Cancer Biotech

Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9 billion acquisition of French cancer firm Advanced Accelerator Applications.
- Source: Biospace
- 796
- October 31, 2017
CAR–T GEP-NETs Market Views neuroendocrine tumors

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.